Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

News SummaryMost relevantAll newsSector newsTweets 

Novo Nordisk B : In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

share with twitter share with LinkedIn share with facebook
share via e-mail
04/13/2012 | 10:15am CEST
News In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

As part of an official Danish state visit to Kenya, Novo Nordisk on 12 April officially launched a programme to make insulin and diabetes care more accessible to poor populations.

In Kenya, 250,000 people are in need of insulin out of which 80,000 are people with an annual income between 1,500-3,000 US dollars. To make insulin more affordable and accessible to this group, Novo Nordisk has in partnership with local organisations and faith-based hospitals and clinics developed a new business model that includes a streamlined supply chain and treatment centres that are closer to the patients' homes.

The project has reduced price mark-ups in the supply chain to the extent that the insulin can be obtained at 20 cents daily, which is equivalent to a third of the previous price on the private market.

The Kenyan project is the first of three pilots to be launched by Novo Nordisk this year. A second one is about to be launched in India, and a third pilot will be launched in Nigeria later in 2012.

The pilot projects will create valuable learnings on how access to insulin and proper diabetes care can be improved for people with diabetes with very low incomes.

Worldwide, there is a population of 46 million people with diabetes who earn between 4 and 10 dollars per day. In 2030, this group is expected to grow to more than 73 million people.

Diabetes in Africa

According to the International Diabetes Federation, the growth of diabetes in Africa is currently the highest in the world. Close to 15 million people in sub-Saharan Africa currently have diabetes, and this number is expected to rise to around 28 million in 2030. It is estimated that 78% of people with diabetes today are undiagnosed.

In Kenya, the International Diabetes Federation estimates that there are currently around one million people with diabetes in Kenya with urban prevalence up to 10%.

Video from Kenya will be available here Monday.

Contacts details:

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVO NORDISK A/S
06/22 NOVO NORDISK A/S : Tresiba® demonstrated no increased risk of major cardiovascul..
06/22 NOVO NORDISK A/S : New LEADER Analysis Shows Victoza Reduces Cardiovascular Risk..
06/22 NOVO NORDISK A/S : CHMP endorses EU label update of Saxenda® based on the LEADER..
06/22 NOVO NORDISK A/S : FDA panel supports cardiovascular indication for Novos diabet..
06/21 NOVO NORDISK A/S : receives positive 17-2 vote from FDA Advisory Committee that ..
06/20 NOVO NORDISK A/S : receives positive 17-2 vote from FDA Advisory Committee that ..
06/19 NOVO NORDISK A/S : Health and Human Services Department (HHS); Food and Drug Adm..
06/19 NOVO NORDISK A/S : - Share repurchase programme
06/17 NOVO NORDISK A/S : files to add Lantus-matching CV data to Tresiba`s European la..
More news
Sector news : Pharmaceuticals - NEC
06/22 MYLAN : shareholders vote against executive pay, re-elect board
06/22 Health stocks help European equities cut losses
06/22DJR. JOHNSON : Missouri Sues Drug Firms Over Opioid Marketing -- WSJ
06/21DJJOHNSON & JOHNSON : J&J Seeking Dismissal of Talc Lawsuits in Missouri
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/22 JUNE BUYS : The 16 Stocks Added To My Fund
06/22 NVO (NVO) Investor Presentation - Slideshow
06/20 FDA Ad Comm backs CV risk claim for Novo's Victoza; shares ahead 1% after hou..
06/18 SANOFI : A Good Bet On Pharma
06/16 Panel Meeting For Victoza And Decision Time For Portola's Anticoagulant
Financials ( DKK)
Sales 2017 115 848 M
EBIT 2017 50 067 M
Net income 2017 38 091 M
Finance 2017 18 034 M
Yield 2017 2,66%
P/E ratio 2017 18,87
P/E ratio 2018 17,11
EV / Sales 2017 4,76x
EV / Sales 2018 4,55x
Capitalization 569 929 M
More Financials
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 32
Average target price 285  DKK
Spread / Average Target -1,9%
Consensus details
EPS Revisions
More Estimates Revisions
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Mads Krogsgaard Chief Science Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S14.02%85 314
JOHNSON & JOHNSON17.10%361 566
ROCHE HOLDING LTD.8.81%224 305
NOVARTIS7.69%214 091
PFIZER4.86%199 854
MERCK AND COMPANY12.15%176 500
More Results